Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Auto and Transport Industry News Can Bapcor Limited (ASX: BAP) bounce back after a 48% plunge and tools segment blow-up? Bapcor Limited (ASX: BAP) shares plunge 18% after FY26 downgrade and tools segment review. Find out what’s behind the fall and whether a turnaround is possible. byVenkateshOctober 20, 2025